The reports of my death have been greatly exaggerated. Mark Twain In July, we summarized the issue of companies acquiring other companies in tax-friendly countries. These so-called "inversions" were not…
Twenty Five. That's it. What are we talking about? Some of the data in yesterday's excellent post by Bruce Booth on Early Stage Venture Scarcity really caught us by surprise. What…
At Lacerta Bio, we're big believers in the therapeutic benefits of drug delivery in its many forms. Today, another drug delivery effort earned an FDA approval. In this case, it's…
This morning, California-based Avanir Pharmaceuticals announced that their combination of dextromethorphan HBr and quinidine sulfate (AVP-923) hit their Phase II endpoints in Alzheimer's Disease: Treatment with AVP-923 was associated…
Thompson Reuters published a good overview of the challenges facing companies developing biosimilars. A few items which stood out for us were: Europe Has Led, But... - While 17…
A few weeks ago, BIO conducted an interesting panel discussion as part of their run up to the BIO Latin America Conference taking place the week in Brazil. The…
Lacerta Bio is pleased to return to Europe for the 20th Anniversary of the BIO-Europe conference. We will be there from Sunday evening through Wednesday afternoon. Look for us in PartneringOne,…
We’re actively seeking guest bloggers for LacertaBio.com! The ideal guest blogger: - Is currently involved in business development and licensing - Currently works for a pharma, biotech, VC, PE,…
This morning we learned that Sanofi is the winner in the "Where on Earth is the Partner for Afrezza?" sweepstakes. We'll defer to the many news outlets for…
Yes, and it might be worth it. Yesterday, Daiichi Sankyo announced an incredible $650 million deal with Florida-based Charleston Laboratories for the development and commercialization of a family of fixed…